Drugmakers, get ready for bigger, faster dealmaking, Moody’s says

Tracy Staton Deal junkies, rejoice. Moody's Investors Service figures pharma M&A will pick up in 2013, after a not-so-exciting 2012. But even if the pace picks up, deal size ...

Report: Antibiotics pipeline lackluster as resistance surges

Emily Mullin As antibiotic resistance grows in the U.S. with the rise in increasingly deadly bacteria, nicknamed "nightmare bacteria," a new report has identified that only ...

Antibiotics upstart Allecra snags €15M VC round amid superbug scare

Ryan McBride Amid an outcry for new options against drug-resistant bacteria, Allecra Therapeutics has taken off with a €15 million ($ 19.6 million) Series A round of venture ...

Biogen Idec, big biotechs trounce pharma players on multiple fronts this decade

Ryan McBride This could be the decade of the big biotech companies, or Big Biotech. A new analysis shows that the biggest biotech players have outperformed a group of pharma giants ...

Analysis: 2012 life sciences VC fundraising and new bets shrivel

Ryan McBride Brace for more dour figures on venture investment in biotech. Despite some bright spots in life sciences venture investing, a new study finds that VC players in biotech ...

Pharma reps aren’t talking about drug risks, study finds

Tracy Staton Doctors aren't getting the skinny on drug side effects from pharma reps, a new study finds. Even the most serious risks are often overlooked, the survey found. And ...

President’s budget takes a big bite out of Medicare drug spending

Tracy Staton Expect plenty of teeth-gnashing in the pharma industry over the next several weeks. President Obama's budget proposal not only proposes accelerated discounts for Medicare ...

Valeant, Actavis team up on two more authorized generics

Tracy Staton Valeant Pharmaceuticals ($ VRX) and Actavis ($ ACT) are getting downright buddy-buddy. Less than a week after partnering up on three skin products, the two companies ...

With patent clock ticking, Amgen plans to shutter Epogen plant

Idled Longmont plant will cost some jobs, but other on-site functions will stay By Tracy Staton In a major milestone for its anemia franchise, Amgen ($AMGN) is preparing to idle production ...

Isis California facility gains GMP certification from EMA

PBR Staff Writer Isis Pharmaceuticals has received Good Manufacturing Practices (GMP) certification to its manufacturing facility located in Carlsbad, California, US, from the EMA for ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS